Avadel Pharmaceuticals' Contingent Value Rights Could Yield Over $1 Billion from Jazz Pharmaceuticals Lawsuits

Reuters

06-30

Avadel Pharmaceuticals' Contingent Value Rights Could Yield Over $1 Billion from Jazz Pharmaceuticals Lawsuits

Avadel Pharmaceuticals plc is currently involved in six lawsuits against Jazz Pharmaceuticals, Inc., with potential settlements being a focal point for the company. The litigation could significantly impact Avadel's financial landscape, with the company's CEO suggesting that just one of these lawsuits, set to go to trial in four months, could yield a recovery exceeding $1 billion. In light of these legal proceedings, Avadel plans to distribute a contingent value right $(CVR)$ to its shareholders, entitling them to any proceeds from these lawsuits. This development comes amidst calls from a significant shareholder, ASL Strategic Value Fund, for Avadel's shareholders to vote against the current director nominees at the upcoming annual meeting, citing a need for a new strategic direction to enhance shareholder value.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avadel Pharmaceuticals plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20250627862428) on June 30, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2547093754"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2547093754\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2547093754?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-30 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2547093754","market":"fut","top_or_hot":-1,"title":"Avadel Pharmaceuticals' Contingent Value Rights Could Yield Over $1 Billion from Jazz Pharmaceuticals Lawsuits","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Avadel Pharmaceuticals' Contingent Value Rights Could Yield Over $1 Billion from Jazz Pharmaceuticals Lawsuits\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/AVDL\">Avadel Pharmaceuticals plc</a> is currently involved in six lawsuits against Jazz Pharmaceuticals, Inc., with potential settlements being a focal point for the company. The litigation could significantly impact Avadel's financial landscape, with the company's CEO suggesting that just one of these lawsuits, set to go to trial in four months, could yield a recovery exceeding $1 billion. In light of these legal proceedings, Avadel plans to distribute a contingent value right <a href=\"https://laohu8.com/S/CVR\">$(CVR)$</a> to its shareholders, entitling them to any proceeds from these lawsuits. This development comes amidst calls from a significant shareholder, ASL Strategic Value Fund, for Avadel's shareholders to vote against the current director nominees at the upcoming annual meeting, citing a need for a new strategic direction to enhance shareholder value.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avadel Pharmaceuticals plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20250627862428) on June 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Avadel Pharmaceuticals' Contingent Value Rights Could Yield Over $1 Billion from Jazz Pharmaceuticals Lawsuits</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAvadel Pharmaceuticals' Contingent Value Rights Could Yield Over $1 Billion from Jazz Pharmaceuticals Lawsuits\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-30 19:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Avadel Pharmaceuticals' Contingent Value Rights Could Yield Over $1 Billion from Jazz Pharmaceuticals Lawsuits\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/AVDL\">Avadel Pharmaceuticals plc</a> is currently involved in six lawsuits against Jazz Pharmaceuticals, Inc., with potential settlements being a focal point for the company. The litigation could significantly impact Avadel's financial landscape, with the company's CEO suggesting that just one of these lawsuits, set to go to trial in four months, could yield a recovery exceeding $1 billion. In light of these legal proceedings, Avadel plans to distribute a contingent value right <a href=\"https://laohu8.com/S/CVR\">$(CVR)$</a> to its shareholders, entitling them to any proceeds from these lawsuits. This development comes amidst calls from a significant shareholder, ASL Strategic Value Fund, for Avadel's shareholders to vote against the current director nominees at the upcoming annual meeting, citing a need for a new strategic direction to enhance shareholder value.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avadel Pharmaceuticals plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20250627862428) on June 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4533","symbol_name":"AQR資本管理(全球第二大對沖基金)","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nNDL9gQVY3:1","article_id":"2547093754","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2547093754","pubTimestamp":1751281269,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Avadel Pharmaceuticals plc is currently involved in six lawsuits against Jazz Pharmaceuticals, Inc., with potential settlements being a focal point for the company. The litigation could significantly impact Avadel's financial landscape, with the company's CEO suggesting that just one of these lawsuits, set to go to trial in four months, could yield a recovery exceeding $1 billion. In light of these legal proceedings, Avadel plans to distribute a contingent value right  to its shareholders, entitling them to any proceeds from these lawsuits. This development comes amidst calls from a significant shareholder, ASL Strategic Value Fund, for Avadel's shareholders to vote against the current director nominees at the upcoming annual meeting, citing a need for a new strategic direction to enhance shareholder value.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gener","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4532":"文艺复兴科技持仓","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","AVDL":"Avadel Pharmaceuticals plc","JAZZ":"爵士制药","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC"},"translate_title":"Avadel Pharmaceuticals的或有价值权利可能从Jazz Pharmaceuticals诉讼中获得超过10亿美元的收益","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVDL":0.9,"JAZZ":0.9},"content_text":"Avadel Pharmaceuticals' Contingent Value Rights Could Yield Over $1 Billion from Jazz Pharmaceuticals Lawsuits\n    \n\nAvadel Pharmaceuticals plc is currently involved in six lawsuits against Jazz Pharmaceuticals, Inc., with potential settlements being a focal point for the company. The litigation could significantly impact Avadel's financial landscape, with the company's CEO suggesting that just one of these lawsuits, set to go to trial in four months, could yield a recovery exceeding $1 billion. In light of these legal proceedings, Avadel plans to distribute a contingent value right $(CVR)$ to its shareholders, entitling them to any proceeds from these lawsuits. This development comes amidst calls from a significant shareholder, ASL Strategic Value Fund, for Avadel's shareholders to vote against the current director nominees at the upcoming annual meeting, citing a need for a new strategic direction to enhance shareholder value.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avadel Pharmaceuticals plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20250627862428) on June 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}